Effects of one of antidiabetic agents, teneligliptin, on the vascular endothelium function of ACS patients with diabetes
- Conditions
- Acute Coronary Syndrome (ACS) and diabetes
- Registration Number
- JPRN-UMIN000018936
- Lead Sponsor
- Saitama Medical Center, Jichi Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
For those who fall into any of the following criteria are excluded from the study: 1. With a condition of significantly elevated blood glucose, multiple medication or insulin treatment is desirable 2. The CPK level is over 1000 after ACS onset with suspected cardiomyopathy 3. With medical history of heart disease 4. With sever ketoacidosis, diabetic coma, or precoma 5. Serious infection 6. Perioperative 7. Serious physical injury 8. Showing hypersensitiveness to any compound of teneligliptin 9. Other conditions where the patient is judged by a physician to be inappropriate to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Count of peripheral blood EPCs (at time of pre-treatment/0 week, and 28 weeks after intervention) 2. Serum DPP-4 activity (at time of pre-treatment/0 week, and 28 weeks after intervention) 3. Serum SDF1-alpha concentration (at time of pre-treatment/0 week, and 28 weeks after intervention)
- Secondary Outcome Measures
Name Time Method 1. Assessment of vascular endothelium function by FMD 2. Heart function test, expansionability, by echocardiography (E/A ratio and e/e' ratio of mitral annulus) 3. Cardiac catheter test, IVUS for coronary artery lesion: plaque cross-sectional area of the lesion 4. Blood glucose level (fasting, postprandial [2 hours from a meal], HbA1c) 5. Serum lipid parameter: fasting serum triglyceride, LDL, HDL, fatty acid 4-fractions, RLP, and Lp(a) 6. Urinary 8-OHdG